The U.S. Health Resources and Services Administration (HRSA) wants to push back the implementation of a final rule issued in January that sets the calculation of the ceiling price for the 340B drug pricing program and imposes a “knowing and intentional” standard in determining whether civil monetary penalties should be assessed when a drug company overcharges a 340B provider.